Compass Therapeutics Faces Investor Claims Investigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy CMPX?
Source: Globenewswire
- Disappointing Trial Results: Compass Therapeutics disclosed that its lead drug candidate tovecimig had a median overall survival of 8.9 months in the COMPANION-002 trial, falling short of the control group's 9.4 months, which has significantly undermined investor confidence and led to a sharp decline in stock price.
- Legal Investigation Launched: Johnson Fistel, PLLP is investigating whether the executive officers of Compass Therapeutics violated federal securities laws, potentially leading to claims for investor losses, highlighting serious concerns regarding the company's compliance.
- Significant Investor Losses: The failure of the clinical trial results to meet expectations has resulted in a substantial drop in Compass Therapeutics' stock price, leaving investors facing potential financial losses and necessitating legal action.
- Law Firm Background: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm that was ranked among the Top 10 Plaintiff Law Firms in 2024, successfully recovering approximately $90.725 million for clients, demonstrating its expertise in protecting investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPX
Wall Street analysts forecast CMPX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.840
Low
8.00
Averages
12.67
High
24.00
Current: 1.840
Low
8.00
Averages
12.67
High
24.00
About CMPX
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compass Therapeutics Advances Clinical Trial for Biliary Tract Cancer
- Clinical Trial Results: Compass Therapeutics' COMPANION-002 trial demonstrated an overall response rate of 17.1% for patients treated with Tovecimig in combination with Paclitaxel, significantly higher than the 5.3% response rate for those receiving Paclitaxel alone, indicating Tovecimig's substantial potential in treating advanced biliary tract cancer.
- Trial Design Details: The study enrolled 168 patients, randomized in a 2:1 ratio, with 111 receiving the Tovecimig and Paclitaxel combination and 57 receiving Paclitaxel alone, all administered at standard doses over 28-day cycles, showcasing a robust trial structure.
- Financial Performance: The company reported a net loss of $66.5 million for 2025, translating to a loss of $0.42 per share, an increase from the previous year's loss of $49.4 million or $0.36 per share, reflecting ongoing pressures from R&D investments.
- Funding Status: As of December 31, 2025, Compass held $209 million in cash and marketable securities, expected to fund operations into 2028, indicating a solid financial management strategy amidst ongoing clinical developments.
See More
Tovecimig Plus Paclitaxel Shows Significant Survival Benefit in BTC Study
- Significant Survival Improvement: The combination of tovecimig and paclitaxel demonstrated a statistically significant improvement in median progression-free survival (PFS) of 4.7 months compared to 2.6 months for paclitaxel alone, resulting in a 56% reduction in progression risk (hazard ratio=0.44, p<0.0001), highlighting the therapy's potential in treating advanced biliary tract cancer patients.
- Overall Survival Analysis: Although overall survival (OS) did not meet statistical significance, crossover patients exhibited a median OS of 12.8 months, significantly higher than the 6.1 months for non-crossover patients (hazard ratio=0.54, p=0.04), indicating the effectiveness of crossover treatment.
- Clinical Trial Results: The COMPANION-002 study revealed an overall response rate (ORR) of 17.1% for tovecimig in combination with paclitaxel, significantly surpassing the 5.3% ORR for paclitaxel alone (p=0.031), providing a new treatment option for patients with advanced biliary tract cancer.
- FDA Application Plans: Compass Therapeutics intends to engage with the FDA in the coming months to discuss these findings and prepare for a Biologics License Application (BLA), aiming to expedite the availability of this crucial therapy to meet the urgent needs of biliary tract cancer patients.
See More
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
- Geopolitical Tensions: Stalled peace negotiations between the U.S. and Iran have led to rising oil prices, raising fresh concerns about inflation and global economic growth, as investors balance strong corporate earnings against geopolitical uncertainties.
- Earnings Performance: Verizon (VZ) reported a better-than-expected Q1, while Domino's Pizza (DPZ) posted disappointing results and announced an additional $1 billion share repurchase program, highlighting the varied market reactions to different companies.
- Acquisition Activity: Shell (SHEL) agreed to acquire ARC Resources (AETUF) for C$32.80 per share, while China blocked Meta's (META) acquisition of AI startup Manus, reflecting the complexities of the global M&A landscape.
- Market Index Fluctuations: Near midday, the Dow was down 0.25%, the Nasdaq down 0.28%, and the S&P 500 down 0.14%, indicating the market's sensitive response to geopolitical tensions and economic data.
See More
Compass Therapeutics Shares Plunge 66% After Clinical Trial Setback
- Clinical Trial Setback: Compass Therapeutics' biliary tract cancer candidate tovecimig missed a key secondary endpoint—overall survival—in a phase 2/3 study, resulting in a ~66% drop in stock price on Monday.
- Crossover Patient Impact: The COMPANION-002 study showed 54% of patients crossed over to the treatment group, complicating results; crossover patients had a median overall survival of 12.8 months compared to 6.1 months for non-crossover patients, indicating data complexity.
- Secondary Endpoint Achieved: While overall survival was not met, the combination of tovecimig and paclitaxel achieved a median progression-free survival of 4.7 months versus 2.6 months for placebo, indicating some efficacy.
- Financial Performance: Compass Therapeutics reported a GAAP EPS of -$0.09, reflecting financial pressure from R&D and clinical trials, suggesting investors need to exercise patience for potential future opportunities.
See More
High Options Volume for Compass Therapeutics and CVR Energy
- Compass Therapeutics Options Activity: Compass Therapeutics Inc (CMPX) has seen an options volume of 19,063 contracts today, equating to approximately 1.9 million shares, which represents a significant 64.4% of its average daily trading volume over the past month.
- High Call Option Volume: Within CMPX, the $2 strike call option has traded 6,050 contracts today, representing around 605,000 underlying shares, indicating strong market expectations for the stock's future appreciation.
- CVR Energy Options Dynamics: CVR Energy Inc (CVI) has recorded an options volume of 6,644 contracts today, approximately 664,400 shares, reflecting 61.9% of its average daily trading volume over the past month, showcasing heightened investor interest.
- Bullish Call Option Trends: For CVI, the $32.50 strike call option has seen 5,023 contracts traded today, representing about 502,300 shares, suggesting a sustained bullish sentiment towards the stock in the market.
See More
Compass Therapeutics Faces Investor Claims Investigation
- Disappointing Trial Results: Compass Therapeutics disclosed that its lead drug candidate tovecimig had a median overall survival of 8.9 months in the COMPANION-002 trial, falling short of the control group's 9.4 months, which has significantly undermined investor confidence and led to a sharp decline in stock price.
- Legal Investigation Launched: Johnson Fistel, PLLP is investigating whether the executive officers of Compass Therapeutics violated federal securities laws, potentially leading to claims for investor losses, highlighting serious concerns regarding the company's compliance.
- Significant Investor Losses: The failure of the clinical trial results to meet expectations has resulted in a substantial drop in Compass Therapeutics' stock price, leaving investors facing potential financial losses and necessitating legal action.
- Law Firm Background: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm that was ranked among the Top 10 Plaintiff Law Firms in 2024, successfully recovering approximately $90.725 million for clients, demonstrating its expertise in protecting investor rights.
See More
Compass Therapeutics Advances Clinical Trial for Biliary Tract Cancer
- Clinical Trial Results: Compass Therapeutics' COMPANION-002 trial demonstrated an overall response rate of 17.1% for patients treated with Tovecimig in combination with Paclitaxel, significantly higher than the 5.3% response rate for those receiving Paclitaxel alone, indicating Tovecimig's substantial potential in treating advanced biliary tract cancer.
- Trial Design Details: The study enrolled 168 patients, randomized in a 2:1 ratio, with 111 receiving the Tovecimig and Paclitaxel combination and 57 receiving Paclitaxel alone, all administered at standard doses over 28-day cycles, showcasing a robust trial structure.
- Financial Performance: The company reported a net loss of $66.5 million for 2025, translating to a loss of $0.42 per share, an increase from the previous year's loss of $49.4 million or $0.36 per share, reflecting ongoing pressures from R&D investments.
- Funding Status: As of December 31, 2025, Compass held $209 million in cash and marketable securities, expected to fund operations into 2028, indicating a solid financial management strategy amidst ongoing clinical developments.
See More
Tovecimig Plus Paclitaxel Shows Significant Survival Benefit in BTC Study
- Significant Survival Improvement: The combination of tovecimig and paclitaxel demonstrated a statistically significant improvement in median progression-free survival (PFS) of 4.7 months compared to 2.6 months for paclitaxel alone, resulting in a 56% reduction in progression risk (hazard ratio=0.44, p<0.0001), highlighting the therapy's potential in treating advanced biliary tract cancer patients.
- Overall Survival Analysis: Although overall survival (OS) did not meet statistical significance, crossover patients exhibited a median OS of 12.8 months, significantly higher than the 6.1 months for non-crossover patients (hazard ratio=0.54, p=0.04), indicating the effectiveness of crossover treatment.
- Clinical Trial Results: The COMPANION-002 study revealed an overall response rate (ORR) of 17.1% for tovecimig in combination with paclitaxel, significantly surpassing the 5.3% ORR for paclitaxel alone (p=0.031), providing a new treatment option for patients with advanced biliary tract cancer.
- FDA Application Plans: Compass Therapeutics intends to engage with the FDA in the coming months to discuss these findings and prepare for a Biologics License Application (BLA), aiming to expedite the availability of this crucial therapy to meet the urgent needs of biliary tract cancer patients.
See More
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
- Geopolitical Tensions: Stalled peace negotiations between the U.S. and Iran have led to rising oil prices, raising fresh concerns about inflation and global economic growth, as investors balance strong corporate earnings against geopolitical uncertainties.
- Earnings Performance: Verizon (VZ) reported a better-than-expected Q1, while Domino's Pizza (DPZ) posted disappointing results and announced an additional $1 billion share repurchase program, highlighting the varied market reactions to different companies.
- Acquisition Activity: Shell (SHEL) agreed to acquire ARC Resources (AETUF) for C$32.80 per share, while China blocked Meta's (META) acquisition of AI startup Manus, reflecting the complexities of the global M&A landscape.
- Market Index Fluctuations: Near midday, the Dow was down 0.25%, the Nasdaq down 0.28%, and the S&P 500 down 0.14%, indicating the market's sensitive response to geopolitical tensions and economic data.
See More
Compass Therapeutics Shares Plunge 66% After Clinical Trial Setback
- Clinical Trial Setback: Compass Therapeutics' biliary tract cancer candidate tovecimig missed a key secondary endpoint—overall survival—in a phase 2/3 study, resulting in a ~66% drop in stock price on Monday.
- Crossover Patient Impact: The COMPANION-002 study showed 54% of patients crossed over to the treatment group, complicating results; crossover patients had a median overall survival of 12.8 months compared to 6.1 months for non-crossover patients, indicating data complexity.
- Secondary Endpoint Achieved: While overall survival was not met, the combination of tovecimig and paclitaxel achieved a median progression-free survival of 4.7 months versus 2.6 months for placebo, indicating some efficacy.
- Financial Performance: Compass Therapeutics reported a GAAP EPS of -$0.09, reflecting financial pressure from R&D and clinical trials, suggesting investors need to exercise patience for potential future opportunities.
See More
High Options Volume for Compass Therapeutics and CVR Energy
- Compass Therapeutics Options Activity: Compass Therapeutics Inc (CMPX) has seen an options volume of 19,063 contracts today, equating to approximately 1.9 million shares, which represents a significant 64.4% of its average daily trading volume over the past month.
- High Call Option Volume: Within CMPX, the $2 strike call option has traded 6,050 contracts today, representing around 605,000 underlying shares, indicating strong market expectations for the stock's future appreciation.
- CVR Energy Options Dynamics: CVR Energy Inc (CVI) has recorded an options volume of 6,644 contracts today, approximately 664,400 shares, reflecting 61.9% of its average daily trading volume over the past month, showcasing heightened investor interest.
- Bullish Call Option Trends: For CVI, the $32.50 strike call option has seen 5,023 contracts traded today, representing about 502,300 shares, suggesting a sustained bullish sentiment towards the stock in the market.
See More
Compass Therapeutics Faces Investor Claims Investigation
- Disappointing Trial Results: Compass Therapeutics disclosed that its lead drug candidate tovecimig had a median overall survival of 8.9 months in the COMPANION-002 trial, falling short of the control group's 9.4 months, which has significantly undermined investor confidence and led to a sharp decline in stock price.
- Legal Investigation Launched: Johnson Fistel, PLLP is investigating whether the executive officers of Compass Therapeutics violated federal securities laws, potentially leading to claims for investor losses, highlighting serious concerns regarding the company's compliance.
- Significant Investor Losses: The failure of the clinical trial results to meet expectations has resulted in a substantial drop in Compass Therapeutics' stock price, leaving investors facing potential financial losses and necessitating legal action.
- Law Firm Background: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm that was ranked among the Top 10 Plaintiff Law Firms in 2024, successfully recovering approximately $90.725 million for clients, demonstrating its expertise in protecting investor rights.
See More
